Compare BioNano Genomics Inc (BNGO) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Las Vegas Sands Corp. — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Las Vegas Sands Corp. trades at $44.49 (market cap $29.67B). The key difference: Las Vegas Sands Corp. is far larger — about 2247.7× BioNano Genomics Inc's market cap, and Las Vegas Sands Corp. pays a 2.46% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | LVS | |
|---|---|---|
Market Cap | $13.20M | $29.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $69.49 |
52-Week Low | $1.09 | $44.78 |
Enterprise Value | $15.81M | $42.07B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
LVS trades at $45.90, down 1.69% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 revenue of $3.59 billion, up 25.3% year-over-year, and EPS of $0.91, beating estimates. Analyst consensus is strongly bullish with a $65.56 price target, though technical indicators show selling pressure near key support at $45.
LVS presents a compelling value opportunity with a P/E of 16.94 and consistent earnings beats, but faces headwinds from high debt levels and bearish technical momentum. Upside potential exists if the stock holds support and executes on growth, while downside risk persists if macroeconomic or regulatory pressures intensify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
